Citius Pharmaceuticals, Inc.(CTXR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CTXR Citius Pharmaceuticals, Inc.

盘后交易 04-09 17:07:22 EDT

0.8430

+0.0131

+1.58%

盘后0.8700

+0.0270+3.20%

16:17 EDT

最高0.8655	最低0.8000	成交量24.94万
今开0.8194	昨收0.8299	日振幅7.89%
总市值1,886万	流通市值1,586万	总股本2,238万
成交额20.73万	换手率1.33%	流通股本1,881万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CTXR","market":"US","secType":"STK","nameCN":"Citius Pharmaceuticals, Inc.","latestPrice":0.843,"timestamp":1775764800000,"preClose":0.8299,"halted":0,"volume":249448,"hourTrading":{"tag":"盘后","latestPrice":0.87,"preClose":0.843,"latestTime":"16:17 EDT","volume":10632,"amount":9247.139472,"timestamp":1775765834584,"change":0.027,"changeRate":0.032028,"amplitude":0.032028},"delay":0,"changeRate":0.01578503434148693,"floatShares":18810000,"shares":22376400,"eps":-2.463725,"marketStatus":"盘后交易","change":0.0131,"latestTime":"04-09 17:07:22 EDT","open":0.8194,"high":0.8655,"low":0.8,"amount":207328.172247,"amplitude":0.078925,"askPrice":0.87,"askSize":185,"bidPrice":0.775,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-2.463725,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1775779200000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.8299,"preHourTrading":{"tag":"盘前","latestPrice":0.8398,"preClose":0.8299,"latestTime":"09:29 EDT","volume":5666,"amount":4443.8513924399995,"timestamp":1775741399341,"change":0.0099,"changeRate":0.011929,"amplitude":0.091336},"postHourTrading":{"tag":"盘后","latestPrice":0.87,"preClose":0.843,"latestTime":"16:17 EDT","volume":10632,"amount":9247.139472,"timestamp":1775765834584,"change":0.027,"changeRate":0.032028,"amplitude":0.032028},"volumeRatio":0.759698,"impliedVol":1.2654,"impliedVolPercentile":0.572},"requestUrl":"/m/hq/s/CTXR","defaultTab":"news","newsList":[{"id":"1119011859","title":"Citius Oncology公布Lymphir™联合帕博利珠单抗治疗复发或难治性妇科癌研究者发起的1期研究积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1119011859","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119011859?lang=zh_cn&edition=full","pubTime":"2026-03-10 20:48","pubTimestamp":1773146891,"startTime":"0","endTime":"0","summary":"Citius Oncology宣布，其Lymphir™联合帕博利珠单抗治疗复发或难治性妇科癌的研究者发起1期临床试验获得了积极的顶线结果。该研究旨在评估该联合疗法的安全性、耐受性及初步疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTOR","CTXR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614109847","title":"Citius Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614109847","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614109847?lang=zh_cn&edition=full","pubTime":"2026-02-25 23:33","pubTimestamp":1772033606,"startTime":"0","endTime":"0","summary":"北京时间2026年02月25日23时33分，Citius Pharmaceuticals, Inc.股票出现波动，股价大幅下挫5.14%。Citius Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.37%。Citius Pharmaceuticals, Inc.公司简介：Citius Pharmaceuticals Inc是一家生物制药公司，致力于开发和商业化一流的重症监护产品，专注于肿瘤治疗、癌症辅助治疗中的抗感染药物以及其他处方药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022523332697a70964&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022523332697a70964&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CTXR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122767016","title":"Citius Oncology与Uniphar达成独家协议 将淋巴瘤药物Lymphir™分销版图扩展至欧盟","url":"https://stock-news.laohu8.com/highlight/detail?id=1122767016","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122767016?lang=zh_cn&edition=full","pubTime":"2026-02-11 21:03","pubTimestamp":1770815018,"startTime":"0","endTime":"0","summary":"生物制药企业Citius Oncology宣布与欧洲领先医疗产品服务商Uniphar签署独家分销协议，正式将其创新淋巴瘤疗法Lymphir™的商业化版图拓展至欧盟市场。\n此次合作将依托Uniphar在欧洲建立的成熟分销网络，加速Lymphir™在欧盟地区的准入进程。该协议不仅强化了Citius Oncology的全球化战略布局，也为欧洲患者提供了更前沿的治疗选择。\nLymphir™作为针对特定淋巴瘤亚型的靶向疗法，此前已在部分国际市场展现出临床潜力。通过本次渠道拓展，Citius Oncology有望进一步提升其在肿瘤治疗领域的国际影响力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTOR","CTXR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610648851","title":"Citius Pharmaceuticals, Inc.盘中异动 临近收盘股价大涨5.34%报0.795美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610648851","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610648851?lang=zh_cn&edition=full","pubTime":"2026-02-10 04:56","pubTimestamp":1770670594,"startTime":"0","endTime":"0","summary":"北京时间2026年02月10日04时56分，Citius Pharmaceuticals, Inc.股票出现波动，股价急速拉升5.34%。Citius Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.31%。Citius Pharmaceuticals, Inc.公司简介：Citius Pharmaceuticals Inc是一家生物制药公司，致力于开发和商业化一流的重症监护产品，专注于肿瘤治疗、癌症辅助治疗中的抗感染药物以及其他处方药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021004563495407bde&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021004563495407bde&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","CTXR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603452537","title":"Citius Pharmaceuticals, Inc.盘中异动 股价大跌5.58%报0.838美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603452537","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603452537?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:39","pubTimestamp":1768228796,"startTime":"0","endTime":"0","summary":"北京时间2026年01月12日22时39分，Citius Pharmaceuticals, Inc.股票出现异动，股价快速跳水5.58%。Citius Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.24%。Citius Pharmaceuticals, Inc.公司简介：Citius Pharmaceuticals Inc是一家生物制药公司，致力于开发和商业化一流的重症监护产品，专注于肿瘤治疗、癌症辅助治疗中的抗感染药物以及其他处方药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011222395697a17693&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011222395697a17693&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CTXR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601185368","title":"Citius Pharmaceuticals, Inc.盘中异动 股价大涨6.13%报0.900美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601185368","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601185368?lang=zh_cn&edition=full","pubTime":"2026-01-05 22:37","pubTimestamp":1767623852,"startTime":"0","endTime":"0","summary":"北京时间2026年01月05日22时37分，Citius Pharmaceuticals, Inc.股票出现波动，股价大幅拉升6.13%。Citius Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.65%。Citius Pharmaceuticals, Inc.公司简介：Citius Pharmaceuticals Inc是一家生物制药公司，致力于开发和商业化一流的重症监护产品，专注于肿瘤治疗、癌症辅助治疗中的抗感染药物以及其他处方药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010522373297a10d89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010522373297a10d89&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CTXR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186772713","title":"Citius Oncology Inc - 直接发行以每股1.09美元购买1,284,404股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1186772713","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186772713?lang=zh_cn&edition=full","pubTime":"2025-12-09 21:33","pubTimestamp":1765287209,"startTime":"0","endTime":"0","summary":"Citius Oncology Inc - 直接发行以每股1.09美元购买1,284,404股普通股","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","CTXR","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111513577","title":"Citius Oncology 宣布以市场定价进行1800万美元的注册直销及私人投资","url":"https://stock-news.laohu8.com/highlight/detail?id=1111513577","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111513577?lang=zh_cn&edition=full","pubTime":"2025-12-09 21:31","pubTimestamp":1765287103,"startTime":"0","endTime":"0","summary":"Citius Oncology 宣布以市场定价进行1800万美元的注册直销及私人投资","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR","BK4007","BK4139","CTXR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178681935","title":"Citius Oncology通过与Er-Kim的独家协议扩展Lymphir™在土耳其和中东国家的分销","url":"https://stock-news.laohu8.com/highlight/detail?id=1178681935","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178681935?lang=zh_cn&edition=full","pubTime":"2025-12-04 21:37","pubTimestamp":1764855430,"startTime":"0","endTime":"0","summary":"Citius Oncology通过与Er-Kim的独家协议扩展Lymphir™在土耳其和中东国家的分销","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTXR","BK4139","BK4007","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108685707","title":"Citius Oncology 宣布 Lymphir™ 上市，作为切肤性 T 细胞淋巴瘤的新型癌症免疫疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1108685707","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108685707?lang=zh_cn&edition=full","pubTime":"2025-12-02 01:01","pubTimestamp":1764608490,"startTime":"0","endTime":"0","summary":"Citius Oncology 宣布在美国商业化推出 Lymphir™，这是一种针对切肤性 T 细胞淋巴瘤的新型癌症免疫疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR","BK4007","BK4139","CTXR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103462096","title":"Citius Pharmaceuticals宣布以纳斯达克规则按市场价格完成600万美元的注册直接发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1103462096","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103462096?lang=zh_cn&edition=full","pubTime":"2025-10-22 04:31","pubTimestamp":1761078671,"startTime":"0","endTime":"0","summary":"Citius Pharmaceuticals宣布以纳斯达克规则按市场价格完成600万美元的注册直接发行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTXR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149323781","title":"Citius Oncology与麦克森签署美国分销协议以支持Lymphir™商业推广","url":"https://stock-news.laohu8.com/highlight/detail?id=1149323781","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149323781?lang=zh_cn&edition=full","pubTime":"2025-10-20 20:37","pubTimestamp":1760963831,"startTime":"0","endTime":"0","summary":"Citius Oncology与麦克森签署美国分销协议以支持Lymphir™商业推广","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCK","LU0742534661.SGD","LU0122379950.USD","LU1506573853.SGD","LU0868494708.USD","LU0203345920.USD","LU1061106388.HKD","LU1934455863.HKD","LU2089984988.USD","BK4588","LU0861579265.USD","LU0965508806.USD","LU0965509101.SGD","LU1934455194.USD","LU0251142724.SGD","LU1430594728.SGD","LU1023059063.AUD","CTOR","LU0314106906.USD","LU1057294990.SGD","LU1814569148.SGD","LU0203347892.USD","BK4585","LU0432979614.USD","BK4139","LU0048573561.USD","LU0251131958.USD","LU2324357040.USD","BK4175","LU1366192091.USD","LU2468319806.SGD","BK4007","BK4533","LU0965509283.SGD","LU1983260115.SGD","LU1037948541.HKD","CTXR","LU1037948897.HKD","LU1585245621.USD","LU0942090050.USD","LU2112291526.USD","LU0868494617.USD","LU0965509010.AUD","LU1934455277.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125386068","title":"Citius Oncology与Eversana签订独家商业化协议，助力计划于2025年第四季度推出Lymphir™","url":"https://stock-news.laohu8.com/highlight/detail?id=1125386068","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125386068?lang=zh_cn&edition=full","pubTime":"2025-10-16 20:48","pubTimestamp":1760618892,"startTime":"0","endTime":"0","summary":"Citius Oncology与Eversana签订独家商业化协议，助力计划于2025年第四季度推出Lymphir™","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTXR","BK4139","CTOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512166443","title":"Citius Pharmaceuticals, Inc.盘中异动 急速下跌5.20%报2.55美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512166443","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512166443?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:31","pubTimestamp":1739889116,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时31分，Citius Pharmaceuticals, Inc.股票出现异动，股价快速下跌5.20%。Citius Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.23%。其相关个股中，Solid Biosciences Inc.、Revolution Medicines Inc C/Wts 17/12/2026 、Aditxt, Inc.涨幅较大，Aditxt, Inc.、Solid Biosciences Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为275.68%、90.87%、59.60%，振幅较大的相关个股有Cns Pharmaceuticals, Inc.、Allakos Inc.、Virpax Pharmaceuticals, Inc.，振幅分别为8.57%、6.84%、6.13%。Citius Pharmaceuticals, Inc.公司简介：Citius Pharmaceuticals Inc是一家生物制药公司，专注于辅助癌症护理，处方产品和干细胞治疗的抗感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021822315696279721&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021822315696279721&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CTXR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511573842","title":"Citius Pharmaceuticals, Inc.盘中异动 急速上涨5.08%报2.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511573842","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511573842?lang=zh_cn&edition=full","pubTime":"2025-02-14 01:24","pubTimestamp":1739467493,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日01时24分，Citius Pharmaceuticals, Inc.股票出现波动，股价大幅上涨5.08%。Citius Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.95%。其相关个股中，Edesa Biotech, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Dominari Holdings Inc.涨幅较大，Edesa Biotech, Inc.、Tc Biopharm  Plc、Genprex, Inc.较为活跃，换手率分别为2959.31%、1202.55%、171.96%，振幅较大的相关个股有Edesa Biotech, Inc.、Immatics N V C/Wts 01/07/2025 、Tc Biopharm  Plc C/Wts 10/02/2028 ，振幅分别为95.15%、92.30%、42.61%。Citius Pharmaceuticals, Inc.公司简介：Citius Pharmaceuticals Inc是一家生物制药公司，专注于辅助癌症护理，处方产品和干细胞治疗的抗感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214012453abcdd470&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214012453abcdd470&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CTXR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510522332","title":"Citius Pharmaceuticals, Inc.盘中异动 大幅跳水5.19%报2.56美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510522332","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510522332?lang=zh_cn&edition=full","pubTime":"2025-02-12 00:57","pubTimestamp":1739293020,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日00时57分，Citius Pharmaceuticals, Inc.股票出现波动，股价急速下挫5.19%。Citius Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.53%。其相关个股中，Omega Therapeutics, Inc.、Lipella Pharmaceuticals Inc.、Oramed Pharmaceuticals Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为2996.60%、1336.48%、437.62%，振幅较大的相关个股有Omega Therapeutics, Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.，振幅分别为143.33%、59.46%、58.60%。Citius Pharmaceuticals, Inc.公司简介：Citius Pharmaceuticals Inc是一家生物制药公司，专注于辅助癌症护理，处方产品和干细胞治疗的抗感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212005700a2421a4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212005700a2421a4c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","CTXR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509205024","title":"Citius Pharmaceuticals, Inc.盘中异动 早盘急速下跌5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509205024","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509205024?lang=zh_cn&edition=full","pubTime":"2025-02-07 00:20","pubTimestamp":1738858803,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日00时20分，Citius Pharmaceuticals, Inc.股票出现异动，股价急速下挫5.28%。Citius Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.25%。其相关个股中，Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Equillium, Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Azitra Inc较为活跃，换手率分别为5770.20%、1515.91%、152.01%，振幅较大的相关个股有Lipella Pharmaceuticals Inc.、Equillium, Inc.、Azitra Inc，振幅分别为120.16%、44.37%、42.43%。Citius Pharmaceuticals, Inc.公司简介：Citius Pharmaceuticals Inc是一家生物制药公司，专注于辅助癌症护理，处方产品和干细胞治疗的抗感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207002004961a2a64&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207002004961a2a64&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","CTXR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509464149","title":"Citius Pharmaceuticals, Inc.盘中异动 股价大跌5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509464149","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509464149?lang=zh_cn&edition=full","pubTime":"2025-02-05 01:03","pubTimestamp":1738688619,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日01时03分，Citius Pharmaceuticals, Inc.股票出现异动，股价快速下挫5.20%。Citius Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.57%。其相关个股中，Cingulate Inc C/Wts 10/12/2026 、Azitra Inc、Estrella Immunopharma Inc C/Wts 29/09/2028涨幅较大，Azitra Inc、Evaxion Biotech As、Quoin Pharmaceuticals Ltd较为活跃，换手率分别为1725.70%、943.84%、555.32%，振幅较大的相关个股有Azitra Inc、Cingulate Inc C/Wts 10/12/2026 、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 ，振幅分别为72.82%、57.14%、49.88%。Citius Pharmaceuticals, Inc.公司简介：Citius Pharmaceuticals Inc是一家生物制药公司，专注于辅助癌症护理，处方产品和干细胞治疗的抗感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205010340987a6254&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205010340987a6254&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","CTXR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507063961","title":"Citius Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507063961","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507063961?lang=zh_cn&edition=full","pubTime":"2025-01-31 23:20","pubTimestamp":1738336802,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日23时20分，Citius Pharmaceuticals, Inc.股票出现异动，股价大幅跳水5.12%。Citius Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.25%。其相关个股中，Nls Pharmaceutics Ltd C/Wts 02/02/2026、Cyclerion Therapeutics, Inc.、Nls Pharmaceutics Ltd.涨幅较大，Nls Pharmaceutics Ltd.、Cyclerion Therapeutics, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为1775.68%、1646.44%、124.31%，振幅较大的相关个股有Nls Pharmaceutics Ltd C/Wts 02/02/2026、Cyclerion Therapeutics, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为63.20%、56.30%、46.27%。Citius Pharmaceuticals, Inc.公司简介：Citius Pharmaceuticals Inc是一家生物制药公司，专注于辅助癌症护理，处方产品和干细胞治疗的抗感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025013123200298776578&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025013123200298776578&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CTXR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507621385","title":"Citius Pharmaceuticals, Inc.盘中异动 早盘快速下跌5.02%报2.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507621385","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507621385?lang=zh_cn&edition=full","pubTime":"2025-01-30 22:40","pubTimestamp":1738248008,"startTime":"0","endTime":"0","summary":"北京时间2025年01月30日22时40分，Citius Pharmaceuticals, Inc.股票出现波动，股价大幅下跌5.02%。Citius Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.08%。其相关个股中，Tectonic Therapeutic, Inc.、Alterity Therapeutics Limited、Kazia Therapeutics Limited涨幅较大，Kazia Therapeutics Limited、Alterity Therapeutics Limited、Silexion Therapeutics Corp较为活跃，换手率分别为933.97%、137.42%、117.86%，振幅较大的相关个股有Immatics N V C/Wts 01/07/2025 、Kazia Therapeutics Limited、Ocean Biomedical Inc C/Wts 14/02/2028 ，振幅分别为56.41%、41.30%、28.90%。Citius Pharmaceuticals, Inc.公司简介：Citius Pharmaceuticals Inc是一家生物制药公司，专注于辅助癌症护理，处方产品和干细胞治疗的抗感染。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130224008a23456de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130224008a23456de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","CTXR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.citiuspharma.com","stockEarnings":[{"period":"1week","weight":-0.0157},{"period":"1month","weight":-0.0108},{"period":"3month","weight":-0.0779},{"period":"6month","weight":-0.3253},{"period":"1year","weight":-0.1498},{"period":"ytd","weight":0.0681}],"compareEarnings":[{"period":"1week","weight":0.0317},{"period":"1month","weight":-0.0033},{"period":"3month","weight":-0.0196},{"period":"6month","weight":0.0352},{"period":"1year","weight":0.3616},{"period":"ytd","weight":-0.0087}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Citius Pharmaceuticals, Inc.于2007年1月23日成立为马萨诸塞州有限责任公司Citius Pharmaceuticals，LLC。该公司总部位于新泽西州克兰福德，是一家专业制药公司，致力于针对重要医疗需求的重症监护产品的开发和商业化，重点是肿瘤学、辅助癌症护理中的抗感染产品和独特的处方产品。该公司的目标是通过提供解决未满足的医疗需求的治疗产品，实现领先的市场地位。随着公司寻求降低与药物开发相关的开发和临床风险，具有大量安全性和有效性数据的先前批准的药物的新配方是核心焦点。公司战略以拥有知识产权和监管保护的产品为中心，同时提供相对于现有治疗方法的竞争优势。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.065068},{"month":2,"riseRate":0.444444,"avgChangeRate":0.005309},{"month":3,"riseRate":0.555556,"avgChangeRate":0.027319},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.068853},{"month":5,"riseRate":0.375,"avgChangeRate":-0.033617},{"month":6,"riseRate":0.5,"avgChangeRate":0.21392},{"month":7,"riseRate":0.5,"avgChangeRate":0.044064},{"month":8,"riseRate":0.25,"avgChangeRate":-0.102382},{"month":9,"riseRate":0.222222,"avgChangeRate":-0.074874},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.053965},{"month":11,"riseRate":0.444444,"avgChangeRate":-0.058176},{"month":12,"riseRate":0.222222,"avgChangeRate":0.017749}],"exchange":"NASDAQ","name":"Citius Pharmaceuticals, Inc.","nameEN":"Citius Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Citius Pharmaceuticals, Inc.(CTXR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Citius Pharmaceuticals, Inc.(CTXR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Citius Pharmaceuticals, Inc.,CTXR,Citius Pharmaceuticals, Inc.股票,Citius Pharmaceuticals, Inc.股票老虎,Citius Pharmaceuticals, Inc.股票老虎国际,Citius Pharmaceuticals, Inc.行情,Citius Pharmaceuticals, Inc.股票行情,Citius Pharmaceuticals, Inc.股价,Citius Pharmaceuticals, Inc.股市,Citius Pharmaceuticals, Inc.股票价格,Citius Pharmaceuticals, Inc.股票交易,Citius Pharmaceuticals, Inc.股票购买,Citius Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Citius Pharmaceuticals, Inc.(CTXR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Citius Pharmaceuticals, Inc.(CTXR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}